Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Stacy Slade

Physician Assistant Las Vegas, NV Physician Assistant

NPI 1669996567 CMS profile 11078224

4475 S Eastern Ave, Las Vegas, NV 89119

Open in the dashboard

General payments

$8,030

285 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stacy Slade of Las Vegas, NV is reported in the CMS Open Payments database as having received $8,030 across 285 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $997 41
2024 General $1,480 65
2023 General $1,653 69
2022 General $1,478 76
2021 General $2,422 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stacy Slade
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Stacy Slade were reported at $997. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Stacy Slade Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,422 $132 $37–$438 $132
2022 $1,478 $155 $48–$522 $149
2023 $1,653 $167 $52–$557 $160
2024 $1,480 $178 $55–$600 $164
2025 $997 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $2,218 15 payments
  2. Sumitomo Pharma America, Inc. $1,306 63 payments
  3. Dendreon Pharmaceuticals LLC $668 17 payments
  4. AbbVie, Inc. $530 26 payments
  5. Urovant Sciences Inc $370 20 payments
  6. Urogen Pharma, Inc. $360 20 payments
  7. Astellas Pharma US Inc $330 13 payments
  8. Antares Pharma, Inc. $266 16 payments
  9. Janssen Biotech, Inc. $264 14 payments
  10. Endo Pharmaceuticals Inc. $261 9 payments
  11. Other $1,457 72 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,291 280 payments
  2. Travel and Lodging $1,586 3 payments
  3. Education $153 2 payments
Products named General payments · program years 2021–2025
  1. AMS 700 CXR RTE KIT $1,786 6 payments
  2. GEMTESA $1,331 64 payments
  3. PROVENGE $668 17 payments
  4. ORGOVYX $383 22 payments
  5. BOTOX $337 15 payments
  6. XIAFLEX $324 12 payments
  7. JELMYTO $318 17 payments
  8. General - Erectile Dysfunction $274 2 payments
  9. ERLEADA $264 14 payments
  10. XYOSTED $247 15 payments
  11. Other $2,674 134 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

889

Median for Physician Assistant: 241

Drug cost

$110,544

Median for Physician Assistant: $4,110

Branded share of claims

30%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 98 $60,487
Gemtesa Vibegron Brand 54 $37,987
Tamsulosin Hcl Generic 390 $4,710
Testosterone Cypionate Generic 48 $2,713
Estradiol Generic 20 $1,263
Finasteride Generic 63 $798
Oxybutynin Chloride Er Oxybutynin Chloride Brand 36 $745
Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst Brand 41 $647
Oxybutynin Chloride Generic 13 $334
Ciprofloxacin Hcl Generic 47 $309

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$53,089

Medicare's payments for the services billed

Medicare patients

384

Average age 74

Services billed

1,532

74 women, 310 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Diabetes 42%
Chronic kidney disease 41%
Ischemic heart disease 37%
Heart failure 26%
Atrial fibrillation 24%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $526
$526 54 —
PROVENGE
  • Dendreon Pharmaceuticals LLC $306
$306 — —
BOTOX
  • AbbVie, Inc. $121
$121 — —
ORGOVYX
  • Sumitomo Pharma America, Inc. $80
  • PFIZER INC. $14
$94 — —
ERLEADA
  • Janssen Biotech, Inc. $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record